Xerox Holdings Corp. reported a 25.7% year-over-year revenue increase to $2.03 billion in Q4 2025, yet fell short of Wall Street expectations. The company's full-year guidance and per-share loss also disappointed analysts, as margin pressures and acquisition integration complexities weigh on its transformation journey.
DXC Technology met Q4 revenue targets with stable sales of $3.19B and an earnings surprise, but cautious guidance and stagnant organic growth highlight the challenges of its strategic transformation toward AI-native services.
Mid-cap stocks offer a compelling blend of established operations and growth potential, but navigating this competitive landscape requires sharp discernment. We analyze one company with promising prospects and two where investors might want to apply the brakes.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
The Federal Reserve's decision to hold interest rates steady signals a strategic pause, not an end to its easing cycle. We break down the immediate and future impacts on everything from credit cards to the housing market.
Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.
Trane Technologies (TT) surpassed Wall Street expectations for Q4 2025, driven by surging demand in commercial HVAC systems and data center infrastructure. The company reported revenue of $5.14B, up 5.5% year-over-year, with earnings per share of $2.86. Management expressed confidence for 2026, citing a record order backlog.
ManpowerGroup surpassed revenue forecasts in Q4 2025, reporting a 7.1% year-over-year increase to $4.71 billion. However, earnings fell short of expectations, highlighting the ongoing pressure on profitability even as demand shows signs of firming.
Ameriprise Financial (NYSE: AMP) reported robust fourth-quarter results for 2025, surpassing revenue expectations with a 13.1% year-over-year sales increase to $5.05 billion. Adjusted earnings per share of $10.83 also came in ahead of analyst forecasts.
First Citizens BancShares delivered Q4 revenue and adjusted EPS above analyst forecasts, yet its stock fell. While management pointed to strong fundamentals, analysts probed pressures on margins, tech spending, and integration challenges.
The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze one company whose competitive moat continues to widen and two others where valuation and market dynamics suggest caution is warranted.
While market gains have been concentrated in a handful of tech giants, a select group of companies across semiconductors, beauty, and banking have delivered consistent, triple-digit returns by mastering the fundamentals of growth, margins, and capital efficiency.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.
SunPower has completed its inaugural installation of high-efficiency Monolith solar panels from REC Silicon in California's Santa Cruz, with local installer Cobalt Power Systems reporting immediate sell-out of initial inventory. The move comes amid surging demand from tech-savvy homeowners and follows SunPower's recent quarterly revenue growth.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
